Pear Therapeutics Inc - Product Pipeline Analysis, 2019 Update
Summary
Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive designed for schizophrenia; reCALL using virtual reality exposure therapy to treat combat posttraumatic stress disorder (PTSD); reVIVE against general anxiety disorder; and PEAR-005 to PEAR-011 for treating pain, major depressive disorder, insomnia, Parkinson's disease and inflammatory conditions. Pear Therapeutics reSET, is an FDA-authorized prescription therapeutic for substance use disorder (SUD) used as an outpatient treatment. The company works in partnership with Center for Technology and Behavioral Health, Dartmouth College, Ehave, Inc., Intellectual Ventures Management LLC, Novartis AG, and others. Pear Therapeutics is headquartered in Boston, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Pear Therapeutics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
- Pear Therapeutics Inc Company Overview
- Pear Therapeutics Inc Company Snapshot
- Pear Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Pear Therapeutics Inc – Pipeline Analysis Overview
- Pear Therapeutics Inc - Key Facts
- Pear Therapeutics Inc - Major Products and Services
- Pear Therapeutics Inc Pipeline Products by Development Stage
- Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status
- Pear Therapeutics Inc Pipeline Products Overview
- Digital Therapeutic - Autism Spectrum Disorder
- Digital Therapeutic - Autism Spectrum Disorder Product Overview
- Digital Therapeutic - Cardiovascular Disease
- Digital Therapeutic - Cardiovascular Disease Product Overview
- Digital Therapeutic - Cognition
- Digital Therapeutic - Cognition Product Overview
- Digital Therapeutic - Epilepsy
- Digital Therapeutic - Epilepsy Product Overview
- Digital Therapeutic - Gastrointestinal Disease
- Digital Therapeutic - Gastrointestinal Disease Product Overview
- Digital Therapeutic - Inflammatory conditions
- Digital Therapeutic - Inflammatory conditions Product Overview
- Digital Therapeutic - Major Depressive Disorder
- Digital Therapeutic - Major Depressive Disorder Product Overview
- Digital Therapeutic - Movement Disorders
- Digital Therapeutic - Movement Disorders Product Overview
- Digital Therapeutic - Oncology
- Digital Therapeutic - Oncology Product Overview
- Digital Therapeutic - Respiratory
- Digital Therapeutic - Respiratory Product Overview
- PEAR-006 - Multiple Sclerosis
- PEAR-006 - Multiple Sclerosis Product Overview
- PEAR-006 - Multiple Sclerosis Clinical Trial
- reCALL
- reCALL Product Overview
- reVIVE
- reVIVE Product Overview
- Somryst
- Somryst Product Overview
- Thrive
- Thrive Product Overview
- Thrive Clinical Trial
- Pear Therapeutics Inc - Key Competitors
- Pear Therapeutics Inc - Key Employees
- Pear Therapeutics Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Pear Therapeutics Inc, Recent Developments
- May 18, 2019: Pear Therapeutics to present data on reSET, for the treatment of substance use disorder, and Pear-004, for the treatment of Schizophrenia, at American Psychiatric Association Annual Meeting
- May 03, 2019: Pear Therapeutics initiates feasibility study to treat depressive symptoms in people with multiple sclerosis
- Jan 07, 2019: Sandoz and Pear Therapeutics announce US launch of reSET-O to help treat opioid use disorder
- Dec 17, 2018: Pear Therapeutics announces initiation of proof of concept study for prescription digital therapeutic in development for the treatment of Schizophrenia
- Dec 11, 2018: Sandoz and Pear Therapeutics get FDA clearance for reSET-O app
- Dec 05, 2018: Pear Therapeutics presents new data on reSET and reSET-O at American Academy of Addiction Psychiatry Annual Meeting and Scientific Symposium
- Nov 20, 2018: Sandoz and Pear Therapeutics launch reSET for SUD patients
- Jan 16, 2018: Magellan Health Continues Innovation and Efforts to Improve Outcomes for Patients with Substance Use Disorder
- Dec 12, 2017: Pear Therapeutics Wins Fierce Innovation Life Science Award for reSET Prescription Digital Therapeutic
- Oct 18, 2017: Pear Therapeutics Receives Expedited Access Pathway Designation from FDA for reSET-O Prescription Digital Therapeutic to Treat Opioid Use Disorder
- Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Pear Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Pear Therapeutics Inc Pipeline Products by Equipment Type
- Pear Therapeutics Inc Pipeline Products by Indication
- Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status
- Pear Therapeutics Inc, Key Facts
- Pear Therapeutics Inc, Major Products and Services
- Pear Therapeutics Inc Number of Pipeline Products by Development Stage
- Pear Therapeutics Inc Pipeline Products Summary by Development Stage
- Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status
- Pear Therapeutics Inc Ongoing Clinical Trials Summary
- Digital Therapeutic - Autism Spectrum Disorder - Product Status
- Digital Therapeutic - Autism Spectrum Disorder - Product Description
- Digital Therapeutic - Cardiovascular Disease - Product Status
- Digital Therapeutic - Cardiovascular Disease - Product Description
- Digital Therapeutic - Cognition - Product Status
- Digital Therapeutic - Cognition - Product Description
- Digital Therapeutic - Epilepsy - Product Status
- Digital Therapeutic - Epilepsy - Product Description
- Digital Therapeutic - Gastrointestinal Disease - Product Status
- Digital Therapeutic - Gastrointestinal Disease - Product Description
- Digital Therapeutic - Inflammatory conditions - Product Status
- Digital Therapeutic - Inflammatory conditions - Product Description
- Digital Therapeutic - Major Depressive Disorder - Product Status
- Digital Therapeutic - Major Depressive Disorder - Product Description
- Digital Therapeutic - Movement Disorders - Product Status
- Digital Therapeutic - Movement Disorders - Product Description
- Digital Therapeutic - Oncology - Product Status
- Digital Therapeutic - Oncology - Product Description
- Digital Therapeutic - Respiratory - Product Status
- Digital Therapeutic - Respiratory - Product Description
- PEAR-006 - Multiple Sclerosis - Product Status
- PEAR-006 - Multiple Sclerosis - Product Description
- PEAR-006 - Multiple Sclerosis - Feasibility Study to Treat Depressive Symptoms in People with Multiple Sclerosis
- reCALL - Product Status
- reCALL - Product Description
- reVIVE - Product Status
- reVIVE - Product Description
- Somryst - Product Status
- Somryst - Product Description
- Thrive - Product Status
- Thrive - Product Description
- Thrive - A Randomized, Sham-controlled Study of PEAR-004 as an Adjunct to Standard-of-care Treatment for Schizophrenia
- Pear Therapeutics Inc, Key Employees
- Pear Therapeutics Inc, Other Locations
- Glossary
- List of Figures
- Pear Therapeutics Inc Pipeline Products by Equipment Type
- Pear Therapeutics Inc Pipeline Products by Development Stage
- Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status